Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
RESEARCH TOOLSreports
Holding CAPR?
Track your performance easily
CAPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.52 - $23.40
Previous CloseN/A
Volume187.65K
Average Volume (3M)1.05M
Market Cap
$672.95M
Enterprise Value$423.30M
Total Cash (Recent Filing)$16.19M
Total Debt (Recent Filing)$13.91M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 06, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding45,469,910
10 Day Avg. Volume742,024
30 Day Avg. Volume1,046,593
Standard Deviation0.73
R-Squared0.09
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)28.97
Price to Cash Flow (P/CF)-14.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue18.22
Enterprise Value/Gross Profit16.81
Enterprise Value/Ebitda-12.72
Forecast
1Y Price Target
$41.67Price Target Upside192.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Capricor Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyDeramiocel treatment showed clear and significant slowing of LVEF reduction at 12 months in clinical trials, highlighting its effectiveness in improving cardiac outcomes.
Market Expansion PotentialFunctional outcomes data could be the basis of EU approval, where the DMD market is relatively underdeveloped, indicating potential for market expansion.
Regulatory MilestonesCapricor Therapeutics has completed the BLA submission for DMD cardiomyopathy, indicating progress in regulatory processes.
Bears Say
Approval UncertaintyThere is uncertainty as deramiocel may not gain regulatory approval, impacting future growth prospects.
Financial PerformanceNippon Shinyaku may not meet revenue forecasts, raising concerns about financial stability.
Regulatory ChallengesThe FDA might require additional data, which could delay the approval process.
---
Ownership Overview
16.80% Insiders
5.02% Mutual Funds
0.05% Other Institutional Investors
67.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $3.52 and its highest was $23.40 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is $672.95M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 35 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.358 by -$0.022.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,469,910 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.358. Following the earnings report the stock price went up 9.344%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Woodline Partners LP. It holds Capricor Therapeutics’s shares valued at 0.
---
Capricor Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.67 (192.01% Upside)
$41.67 (192.01% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 12.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
262.74%
12-Months-Change
Fundamentals
Return on Equity
-102.63%
Trailing 12-Months
Asset Growth
150.19%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
CAPR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Capricor's strategic progress towards FDA approval and market expansion for deramiocel, bolstered by strong financial positioning and positive payer feedback. However, challenges like revenue decline and increased net loss were noted. Despite these challenges, the advancements and positive outlook position the company favorably for future growth.Read More>---
CAPR Stock 12 Month Forecast
Average Price Target
$41.67
▲(192.01% Upside)
Technical Analysis
Mesoblast
―
Sorrento Therapeutics
―
CryoPort
―
Brainstorm Cell Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering CAPR
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+177.81%
assigned a buy rating 28 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +177.81% per trade.
---